Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of HPP737 in Healthy Subjects
NCT06584058Phase 1Not yet recruiting
- Sponsor
- Newsoara Biopharma
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HPP737 in psoriasis, sponsored by Newsoara Biopharma. Primary endpoints: Peak Concentration up to 12 months, Time to Peak Concentration up to 12 months and 9 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
HPP737
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06584058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584058.